GSK Bio
NEWS
Provides students with the opportunity to design new drug-like molecules targeting fibrotic diseases and malaria with cutting-edge drug discovery software
Advancing proprietary pipeline; solid progress in partnered programs
What did Dr. Victor Frankenstein use to bring his “monster” to life? Electricity. And as much as that seemed far-fetched when Mary Shelley wrote the novel in 1818, the use of electrical devices and electricity to treat diseases has advanced significantly—and continues to advance.
Nouscom announced today that it has appointed John F. McDonald as an independent director to its Board of Directors.
Facilities in The Schrödinger Building to bring together AI experts and biologists
Kymera Therapeutics secured $65 million in a Series B funding round that was supported, in part, by the investment arms of Pfizer and Sanofi.
Biopharma companies make key appointments to fill leadership positions. Let’s take a look!
There are no treatments for autism, but that’s not stopping research into the development of therapies for core symptoms of autism spectrum disorder. This week, London-based AMO Pharma reported Phase II results from its investigational glycogen synthase kinase 3 (GSK3) beta inhibitor, AMO-02 (tideglusib).
In an interview with S&P Global Market Intelligence, Alex Hoos, head of oncology at GSK, said the company could narrow its drug development focus to aim at products that will generate growth.
JOBS
IN THE PRESS